Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXT6YT)

Drug Name

ALXN2030 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Phase 1	[1]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C3 messenger RNA (C3 mRNA)	TTXA5VP	CO3_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05501717) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alexion